Eric R. Olson
2021
In 2021, Eric R. Olson earned a total compensation of $1.4M as Chief Scientific Officer at Syros Pharmaceuticals, a 20% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $180,686 |
---|---|
Option Awards | $746,191 |
Salary | $481,115 |
Other | $576 |
Total | $1,408,568 |
Olson received $746.2K in option awards, accounting for 53% of the total pay in 2021.
Olson also received $180.7K in non-equity incentive plan, $481.1K in salary and $576 in other compensation.
Rankings
In 2021, Eric R. Olson's compensation ranked 7,521st out of 12,415 executives tracked by ExecPay. In other words, Olson earned more than 39.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 7,521 out of 12,415 | 39th |
Division Manufacturing | 3,312 out of 5,508 | 40th |
Major group Chemicals And Allied Products | 1,467 out of 2,378 | 38th |
Industry group Drugs | 1,306 out of 2,099 | 38th |
Industry Pharmaceutical Preparations | 962 out of 1,549 | 38th |
Source: SEC filing on April 21, 2023.
Olson's colleagues
We found three more compensation records of executives who worked with Eric R. Olson at Syros Pharmaceuticals in 2021.
News
Syros Pharmaceuticals CEO Nancy Simonian's 2023 pay falls 59% to $1.4M
April 23, 2024
Syros Pharmaceuticals CEO Nancy Simonian's 2022 pay rises 12% to $3.5M
April 21, 2023
Syros Pharmaceuticals CEO Nancy Simonian's 2021 pay jumps 23% to $3.1M
April 21, 2022
Syros Pharmaceuticals CEO Nancy Simonian's 2020 pay falls 30% to $2.5M
April 29, 2021
Syros Pharmaceuticals CEO Nancy Simonian's 2019 pay rises 19% to $3.6M
April 28, 2020
Syros Pharmaceuticals CEO Nancy Simonian's 2018 pay jumps 36% to $3M
April 25, 2019